Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

The study aims to evaluate the molecular mechanism underlying the erythroid response observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelodysplasia Anemia Anemia, Aplastic Anemia, Refractory Anemia, Refractory, with Excess of Blasts Aplastic Anemia Bone Marrow Diseases Bone Marrow Failure Disorders Hematologic Diseases Hemic and Lymphatic Diseases Myelodysplastic Syndromes Myelofibrosis Myeloproliferative Disorders Primary Myelofibrosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ematologia, AO SS. Antonio e Biagio, Alessandria, AL, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 18 and older
Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia
transfusion-dependent anemia undergoing chelation therapy with deferasirox or deferoxamine

Exclusion criteria

none

Treatment and study plan

Primary outcomes

To assess the molecular mechanism underlying the erythroid response

Time frame: 12 months

The primary outcome is to evaluate the molecular mechanism underlying the erythroid response (hemogoblin increase and reduction or elimination of trasfusion dependence) observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina

Sponsors and collaborators

Lead sponsor

Fondazione Italiana Sindromi Mielodisplastiche-ETS

Other

Registry information

Official study title

Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Acronym: BIOFER12

Important dates

Study start: 2013
Primary completion: 2018
Study completion: 2019
First posted: Oct 8, 2013
Registry last updated: Feb 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed